Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Taehwan Park, Chang-ju Choi, Yeera Choi & Dong-Churl Suh. (2016) Cost-effectiveness of cetuximab for colorectal cancer. Expert Review of Pharmacoeconomics & Outcomes Research 16:6, pages 667-677.
Read now
Read now
Kelly Lien, Scott Berry, Yoo-Joung Ko & Kelvin KW Chan. (2015) The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?. Expert Review of Pharmacoeconomics & Outcomes Research 15:1, pages 81-100.
Read now
Read now
Articles from other publishers (15)
Mehmet Akif Erişen & Fatma Özlem Yılmaz. (2023) Comparison of chemotherapy treatment administration via venous port and peripheral vascular access in terms of quality of life and costs. Quality of Life Research 32:7, pages 1897-1908.
Crossref
Crossref
Mikyung Kelly Seo & John Cairns. (2018) Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer. PLOS ONE 13:9, pages e0204496.
Crossref
Crossref
Daniel A. GoldsteinBilal B. AhmadQiushi ChenTurgay AyerDavid H. HowardJoseph LipscombBassel F. El-RayesChristopher R. Flowers. (2015) Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. Journal of Clinical Oncology 33:32, pages 3727-3732.
Crossref
Crossref
A. Lange, A. Prenzler, M. Frank, M. Kirstein, A. Vogel & J.M. von der Schulenburg. (2014) A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. European Journal of Cancer 50:1, pages 40-49.
Crossref
Crossref
Henry WC Leung, Agnes LF Chan, Matthew SH Leung & Chin-Li Lu. (2013) Systematic Review and Quality Assessment of Cost-Effectiveness Analysis of Pharmaceutical Therapies for Advanced Colorectal Cancer. Annals of Pharmacotherapy 47:4, pages 506-518.
Crossref
Crossref
Livio Garattini, Katelijne van de Vooren & Alberto Zaniboni. (2013) Ethics for end-of-life treatments: Metastatic colorectal cancer is one example. Health Policy 109:1, pages 97-103.
Crossref
Crossref
Takaaki Mizuguchi, Naho Ohara, Mika Iida, Ryunosuke Ninomiya, Shinji Wada, Yoshiaki Kiso, Kazuki Saito & Kenichi Akaji. (2012) Evaluation of dimerization–inhibitory activities of cyclic peptides containing a β-hairpin loop sequence of the EGF receptor. Bioorganic & Medicinal Chemistry 20:19, pages 5730-5737.
Crossref
Crossref
N. Mittmann, H.-J. Au, D. Tu, C. J. O'Callaghan, P. K. Isogai, C. S. Karapetis, J. R. Zalcberg, W. K. Evans, M. J. Moore, J. Siddiqui, B. Findlay, B. Colwell, J. Simes, P. Gibbs, M. Links, N. C. Tebbutt & D. J. Jonker. (2009) Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. JNCI Journal of the National Cancer Institute 101:17, pages 1182-1192.
Crossref
Crossref
Takaaki Mizuguchi, Hiromasa Uchimura, Taeko Kakizawa, Tooru Kimura, Shigeyuki Yokoyama, Yoshiaki Kiso & Kazuki Saito. (2009) Inhibitory effect of a dimerization-arm-mimetic peptide on EGF receptor activation. Bioorganic & Medicinal Chemistry Letters 19:12, pages 3279-3282.
Crossref
Crossref
Kjell Johansson, Ingrid Miljeteig & Ole Norheim. (2009) Høykostnadsmedisin – mangler vi åpne og legitime prosedyrer for prioritering?. Tidsskrift for Den norske legeforening 129:1, pages 17-20.
Crossref
Crossref
Jacques Bernier. (2008) Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck. Nature Clinical Practice Oncology 5:12, pages 705-713.
Crossref
Crossref
Dina K. Patel. (2012) Clinical Use of Anti‐Epidermal Growth Factor Receptor Monoclonal Antibodies in Metastatic Colorectal Cancer. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28:11P2.
Crossref
Crossref
Helena Linardou, Issa J Dahabreh, Dimitra Kanaloupiti, Fotios Siannis, Dimitrios Bafaloukos, Paris Kosmidis, Christos A Papadimitriou & Samuel Murray. (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. The Lancet Oncology 9:10, pages 962-972.
Crossref
Crossref
Greg M. Thurber, Michael M. Schmidt & K. Dane Wittrup. (2008) Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Advanced Drug Delivery Reviews 60:12, pages 1421-1434.
Crossref
Crossref
Marko ObradovicAles MrharMitja Kos. (2008)
Cost–effectiveness of
UGT1A1
genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer
. Pharmacogenomics 9:5, pages 539-549.
Crossref
Crossref